Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
出版年份 2021 全文链接
标题
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
作者
关键词
-
出版物
BMJ Open
Volume 11, Issue 4, Pages e045844
出版商
BMJ
发表日期
2021-04-08
DOI
10.1136/bmjopen-2020-045844
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study
- (2020) Ikuro Matsuba et al. Diabetes Technology & Therapeutics
- Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
- (2020) Liang-Kung Chen et al. Journal of the American Medical Directors Association
- Japanese Clinical Practice Guideline for Diabetes 2019
- (2020) Eiichi Araki et al. Journal of Diabetes Investigation
- Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
- (2020) Yuka Goto et al. Endocrine Connections
- Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
- (2019) Derek LeRoith et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report
- (2019) Megumi Yasuda et al. Journal of Diabetes Investigation
- Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
- (2019) Pedro Monteiro et al. AGE AND AGEING
- Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study
- (2019) Kohei Kaku et al. Expert Opinion On Drug Safety
- 12. Older Adults: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial
- (2019) Hajime Yamakage et al. Journal of Diabetes Investigation
- Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
- (2018) Ren Matsuba et al. DIABETES OBESITY & METABOLISM
- The Development of a Patient-Reported Outcome Measure for Geriatric Care: The Older Persons and Informal Caregivers Survey Short Form (TOPICS-SF)
- (2018) Angelina M.M. Santoso et al. VALUE IN HEALTH
- Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
- (2018) Takashi Sasaki et al. Journal of Diabetes Investigation
- Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus
- (2018) Shinji Kamei et al. Journal of Diabetes Research
- There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study
- (2018) Tomoe Kinoshita et al. Diabetes Therapy
- There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study
- (2018) Tomoe Kinoshita et al. Diabetes Therapy
- Ipragliflozin, an SGLT 2 Inhibitor, Reduces Body Weight and Fat Mass, but not Muscle Mass, in Japanese Type 2 Diabetic Patients Treated with Insulin: A Randomized Clinical Trial
- (2018) Hideka Inoue et al. Journal of Diabetes Investigation
- Shortage of energy intake rather than protein intake is associated with sarcopenia in elderly patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort
- (2018) Takuro Okamura et al. Journal of Diabetes
- Patient Reported Outcomes (PROs) used in recent Phase 3 trials for Type 2 Diabetes: A review of concepts assessed by these PROs and factors to consider when choosing a PRO for future trials
- (2016) Matthew Reaney et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Increased grip strength with sodium-glucose cotransporter 2
- (2016) Motoaki Sano et al. Journal of Diabetes
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- (2015) Ian J Neeland et al. Diabetes & Vascular Disease Research
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
- (2015) Linda A Gallo et al. Diabetes & Vascular Disease Research
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- New IDF Guideline for managing type 2 diabetes in older people
- (2014) Trisha Dunning et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- If it does not significantly change HbA1clevels why should we waste time on it? A plea for the prioritization of psychological well-being in people with diabetes
- (2014) A. Jones et al. DIABETIC MEDICINE
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
- (2013) Ronald C.W. Ma et al. Annals of the New York Academy of Sciences
- Guidelines Abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 Update
- (2013) JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Diabetes Mellitus in Older People: Position Statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes
- (2012) Alan Sinclair et al. Journal of the American Medical Directors Association
- European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus. Executive Summary
- (2011) Alan J. Sinclair et al. DIABETES & METABOLISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started